发布求助
文献互助 智能选刊 最新文献

Cancer treatment reports最新文献

筛选
英文 中文
Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. 持续输注长春碱5天用于转移性乳腺癌经皮肝动脉化疗。
Cancer treatment reports Pub Date : 1987-11-01
G Fraschini, G Fleishman, C Charnsangavej, C H Carrasco, G N Hortobagyi
{"title":"Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer.","authors":"G Fraschini,&nbsp;G Fleishman,&nbsp;C Charnsangavej,&nbsp;C H Carrasco,&nbsp;G N Hortobagyi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We assessed the therapeutic efficacy and toxicity of continuous hepatic infusion of vinblastine in the treatment of breast cancer predominantly metastatic to the liver. Twenty-six patients previously treated with one or more chemotherapeutic regimens received vinblastine at a dose of 2.0 mg/m2 daily for 5 days, via percutaneously inserted intra-arterial catheters, at 3-4-week intervals. Nine of 25 evaluable patients (36%) achieved partial response and four (16%) had minor response. For responding patients, the median time to disease progression was 21 weeks (range, 12-99), with a median survival of 11 months (range, 4-29) from the beginning of hepatic arterial infusion. The toxicity of the treatment was acceptable, and drug-related effects were comparable to those seen in patients with breast cancer treated by iv continuous infusion of vinblastine at slightly lower doses. We observed two episodes of transient inappropriate antidiuretic hormone secretion. Percutaneous hepatic arterial infusion of vinblastine had significant activity in the treatment of breast cancer metastatic to the liver.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1001-5"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14796895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibitory action of flurbiprofen and mopidamole on tumor lung metastasis formation in mice. 氟比洛芬和莫替莫对小鼠肿瘤肺转移形成的抑制作用。
Cancer treatment reports Pub Date : 1987-11-01
A Mamytbeková, K Rezábek, J Grimová, J Svobodová
{"title":"Inhibitory action of flurbiprofen and mopidamole on tumor lung metastasis formation in mice.","authors":"A Mamytbeková,&nbsp;K Rezábek,&nbsp;J Grimová,&nbsp;J Svobodová","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Flurbiprofen, 0.25 mg/kg, administered to mice orally once daily during 3 days prior to an iv transplantation of Lewis lung carcinoma cells, protected 50%-57% of experimental animals from the formation of lung tumor colonies. With the daily dose of 1.0 mg/kg, this effect was less pronounced. Mopidamole, twice daily 90 mg/kg orally during 3 days, did not have this effect.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1089-90"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14796900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective treatment of metastatic lymph nodes with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin. 局部热疗联合含博来霉素的温敏脂质体选择性治疗转移性淋巴结。
Cancer treatment reports Pub Date : 1987-11-01
S Maekawa, K Sugimachi, M Kitamura
{"title":"Selective treatment of metastatic lymph nodes with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin.","authors":"S Maekawa,&nbsp;K Sugimachi,&nbsp;M Kitamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Temperature-sensitive liposomes are designed to break down and release their contents preferentially at temperatures attainable by local hyperthermia. The antitumor effects of hyperthermia and anticancer drugs selectively delivered by temperature-sensitive liposomes in metastatic lymph nodes in rats were determined. Temperature-sensitive liposomes containing bleomycin (BLM) were injected sc into the dorsal surface of the right hindfoot of rats bearing AH66 ascites tumor implanted 7 days previously into a right popliteal lymph node. To break down these temperature-sensitive liposomes preferentially in the metastatic lymph nodes and to achieve the synergistic effects of local hyperthermia and BLM, we applied local hyperthermia to the right popliteal lymph node by making use of a water bath at 44 degrees C for 20 minutes. There was a significant difference in suppression of tumor growth and prolonged survival in rats receiving both temperature-sensitive liposomes containing BLM and local hyperthermia, compared with groups receiving hyperthermia alone, water solution of BLM alone, or a combination of both (P less than 0.05). The possibility that hyperthermia plus temperature-sensitive liposomes will enhance therapy for patients with metastatic lymph nodes warrants attention.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1053-9"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13592690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study. 卡铂或伊普罗铂治疗晚期非小细胞肺癌:癌症和白血病B组研究
Cancer treatment reports Pub Date : 1987-11-01
H Kreisman, S Ginsberg, K J Propert, F Richards, S Graziano, M Green
{"title":"Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study.","authors":"H Kreisman,&nbsp;S Ginsberg,&nbsp;K J Propert,&nbsp;F Richards,&nbsp;S Graziano,&nbsp;M Green","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The effect of the cisplatin analogs carboplatin (CBDCA) or iproplatin (CHIP) was evaluated in patients with extensive non-small cell lung cancer. The randomized phase II design was used to achieve balance between patient groups and comparison of response rates was not a primary objective of the study. CBDCA (400 mg/m2 iv) or CHIP (270 mg/m2 iv) was administered every 4 weeks until relapse of disease. Overall, 11 of 70 patients (16%; 95% confidence interval: 7%-25%) responded to CBDCA and five of 71 patients (7%; 95% confidence interval: 1%-13%) responded to CHIP. There were two complete responses to CHIP and none to CBDCA. The most frequent severe or life-threatening toxic effects were thrombocytopenia and leukopenia. Median survival for patients receiving CBDCA was 6.5 months; for those on CHIP it was 5.0 months (P = 0.59). CBDCA is probably active in patients with non-small cell lung cancer whereas CHIP has limited activity. Further evaluation of CBDCA as part of combination chemotherapy for non-small cell lung cancer is warranted.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1049-52"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13962080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How large should a phase II trial of a new drug be? 一种新药的二期试验应该有多大?
Cancer treatment reports Pub Date : 1987-11-01
R Simon
{"title":"How large should a phase II trial of a new drug be?","authors":"R Simon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A number of statistical designs for phase II trials have been published. These designs are critically reviewed. A new design is also introduced. Data are presented on the response rates observed for new chemotherapeutic agents introduced by the National Cancer Institute since 1975. Based upon this material, it is recommended that two-stage designs with a target sample size of 35-50 patients and substantial probability of early termination are usually appropriate. It is also recommended that for active drugs, two to three such trials are necessary to estimate the response rate with reasonable precision. Precise estimation of phase II response rates is not always important, however. For very rare diseases or situations where several dose levels of a biologic are to be evaluated, selection designs may be most appropriate. Such designs are described. Tables are presented to facilitate the design of new agent phase II clinical trials.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1079-85"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14442799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. caracemide治疗晚期或复发性非小细胞肺癌的II期研究。
Cancer treatment reports Pub Date : 1987-11-01
C P Belani, M Eisenberger, D Van Echo, D Hiponia, J Aisner
{"title":"Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.","authors":"C P Belani,&nbsp;M Eisenberger,&nbsp;D Van Echo,&nbsp;D Hiponia,&nbsp;J Aisner","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1099-100"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13962082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of deoxydoxorubicin in patients with advanced liver cancer. 脱氧多柔比星治疗晚期肝癌的II期研究。
Cancer treatment reports Pub Date : 1987-11-01
D J Perry, D A Van Echo, R Mick
{"title":"Phase II study of deoxydoxorubicin in patients with advanced liver cancer.","authors":"D J Perry,&nbsp;D A Van Echo,&nbsp;R Mick","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1117-8"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14251192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy. 随机、双盲、交叉研究比较丙氯哌嗪和劳拉西泮与大剂量甲氧氯普胺和劳拉西泮对细胞毒性化疗患者呕吐的控制效果。
Cancer treatment reports Pub Date : 1987-11-01
J F Bishop, M Wolf, J P Matthews, K Scott, S Ackland, K Yuen, C Morton, B L Hillcoat, I A Cooper
{"title":"Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy.","authors":"J F Bishop,&nbsp;M Wolf,&nbsp;J P Matthews,&nbsp;K Scott,&nbsp;S Ackland,&nbsp;K Yuen,&nbsp;C Morton,&nbsp;B L Hillcoat,&nbsp;I A Cooper","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To further define optimal combinations of antiemetics, high-dose metoclopramide and lorazepam (M+L) were compared with prochlorperazine and lorazepam (P+L) in a randomized, double-blind, cross-over study. Both patient and observer assessments were documented in 66 patients receiving cisplatin and noncisplatin chemotherapy. M+L significantly reduced the severity of vomiting (P = 0.01), duration of vomiting (P = 0.05), and number of vomiting episodes (P = 0.003). Comparing the severity or duration of nausea, M+L and P+L were not significantly different. M+L significantly reduced severity of vomiting (P = 0.005) and number of vomiting episodes (P = 0.03) in the cisplatin subset. The number of vomiting episodes was also reduced in the noncisplatin subset (P = 0.03). When asked to nominate a preferred regimen, 41% of patients preferred P+L, 35% preferred M+L, and 24% rated them equally. M+L was associated with significantly more anxiety and less sedation than P+L. Patient assessments produced similar results to observer assessments but gave a broader understanding of our patients' tolerance to chemotherapy. M+L is a superior regimen in controlling vomiting induced by chemotherapy.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1007-11"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14442797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma. 高剂量脉冲氯苯丁酸治疗晚期低级别非霍奇金淋巴瘤。
Cancer treatment reports Pub Date : 1987-11-01
C S Portlock, D S Fischer, E Cadman, W B Lundberg, A Levy, S Bobrow, J R Bertino, L Farber
{"title":"High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma.","authors":"C S Portlock,&nbsp;D S Fischer,&nbsp;E Cadman,&nbsp;W B Lundberg,&nbsp;A Levy,&nbsp;S Bobrow,&nbsp;J R Bertino,&nbsp;L Farber","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>High-dose pulse chlorambucil was given orally at a dose of 16 mg/m2 daily for 5 consecutive days each month, as reported by Cadman et al. It was used to treat 33 patients with advanced, low-grade non-Hodgkin's lymphoma. With median follow-up of 4.2+ years, 70% of the patients achieved objective response. Eleven of 24 patients with follicular small cleaved cell lymphoma (FSCL) had pathological complete response; nine of 24 with FSCL and three of seven with small lymphocytic lymphoma had partial response. Median disease-free survival was 28 months. Actuarial survival for all patients was 60% at 5 years from initiation of therapy. Treatment toxicity was minimal. Pulse chlorambucil is an effective and minimally toxic palliative therapy for advanced FSCL.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1029-31"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14796896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of recombinant beta interferon in advanced colorectal cancer. 重组干扰素治疗晚期结直肠癌的II期临床试验。
Cancer treatment reports Pub Date : 1987-10-01
P K Lillis, T D Brown, K Beougher, J Koeller, S G Marcus, D D Von Hoff
{"title":"Phase II trial of recombinant beta interferon in advanced colorectal cancer.","authors":"P K Lillis,&nbsp;T D Brown,&nbsp;K Beougher,&nbsp;J Koeller,&nbsp;S G Marcus,&nbsp;D D Von Hoff","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Betaseron is a genetically altered recombinant beta interferon with in vitro properties equivalent to those of native beta interferon. Nineteen patients with measurable advanced colorectal carcinoma who had no previous chemotherapy were given 30 X 10(6) IU Betaseron by iv push on Days 1-5 and 8-12 of each 28-day cycle. One of 17 evaluable patients had a complete response after nine courses of treatment which has been sustained greater than 9 months. The overall response rate was 6% (95% confidence limits, 0%-18%). Treatment was well tolerated with toxic effects consisting of fever, flu-like symptoms, nausea and vomiting, and transient mild granulocytopenia and liver function abnormalities. All toxic effects were World Health Organization (WHO) grade less than or equal to 2. No interferon neutralizing antibody activity was detected. Phase I and preclinical data support further investigation of Betaseron with dose escalation to tolerance for individual patients, as well as investigation of concomitant therapy with 5-fluorouracil, in an attempt to improve the observed response rate in colorectal cancer.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 10","pages":"965-7"},"PeriodicalIF":0.0,"publicationDate":"1987-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14436101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信